- Home
- GUTS vs ADVM Comparison
GUTS vs ADVM Comparison
Compare GUTS & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- ADVM
- Stock Information
- Founded
- GUTS 2010
- ADVM 2006
- Country
- GUTS United States
- ADVM United States
- Employees
- GUTS N/A
- ADVM N/A
- Industry
- GUTS
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GUTS
- ADVM Health Care
- Exchange
- GUTS NYSE
- ADVM Nasdaq
- Market Cap
- GUTS 58.8M
- ADVM 47.4M
- IPO Year
- GUTS 2024
- ADVM 2014
- Fundamental
- Price
- GUTS $1.58
- ADVM $2.35
- Analyst Decision
- GUTS Buy
- ADVM Strong Buy
- Analyst Count
- GUTS 1
- ADVM 5
- Target Price
- GUTS $10.00
- ADVM $23.80
- AVG Volume (30 Days)
- GUTS 930.5K
- ADVM 346.6K
- Earning Date
- GUTS 08-13-2025
- ADVM 08-11-2025
- Dividend Yield
- GUTS N/A
- ADVM N/A
- EPS Growth
- GUTS N/A
- ADVM N/A
- EPS
- GUTS N/A
- ADVM N/A
- Revenue
- GUTS $60,000.00
- ADVM $1,000,000.00
- Revenue This Year
- GUTS N/A
- ADVM N/A
- Revenue Next Year
- GUTS N/A
- ADVM $18.82
- P/E Ratio
- GUTS N/A
- ADVM N/A
- Revenue Growth
- GUTS N/A
- ADVM N/A
- 52 Week Low
- GUTS $0.87
- ADVM $1.78
- 52 Week High
- GUTS $4.92
- ADVM $10.14
- Technical
- Relative Strength Index (RSI)
- GUTS 42.52
- ADVM 41.22
- Support Level
- GUTS $1.54
- ADVM $2.14
- Resistance Level
- GUTS $1.82
- ADVM $2.60
- Average True Range (ATR)
- GUTS 0.18
- ADVM 0.22
- MACD
- GUTS -0.07
- ADVM -0.01
- Stochastic Oscillator
- GUTS 5.06
- ADVM 12.39
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.